Eli Lilly and Company is a major pharmaceutical (biopharma) company. It lobbies Congress on drug pricing and reimbursement, specifically matters tied to implementing the prescription drug provisions of the Inflation Reduction Act of 2022. Filings show it spent about $320,000 and used Tiber Creek Health Strategies for lobbying.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
mr JAMES BRYANT HALL ii
The latest disclosures for this client.
TIBER CREEK HEALTH STRATEGIES, INC.
Q2YTIBER CREEK HEALTH STRATEGIES, INC.
Q1YTIBER CREEK HEALTH STRATEGIES, INC.
The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
TIBER CREEK HEALTH STRATEGIES, INC.
TIBER CREEK HEALTH STRATEGIES, INC.
Q3YTIBER CREEK HEALTH STRATEGIES, INC.
Q2YTIBER CREEK HEALTH STRATEGIES, INC.
Q1